Search

Displaying results 8511 - 8520 of 9314 in total
  1. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  2. Drug

    XmAb24306

    go.drugbank.com/drugs/DB17526
    Investigational

    It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.

  3. Drug

    TORL-2-307

    go.drugbank.com/drugs/DB18376
    Experimental

    TORL-2307 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and pancreatic cancer.

  4. Drug

    Naporafenib

    go.drugbank.com/drugs/DB18865
    Investigational

    Naporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).

  5. Drug

    Tobemstomig

    go.drugbank.com/drugs/DB18987
    Investigational

    Tobemstomig is under investigation in clinical trial NCT05908786 (A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular

  6. Drug

    Pamapimod

    go.drugbank.com/drugs/DB19169
    Investigational

    Pamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).

  7. Drug

    Tigozertinib

    go.drugbank.com/drugs/DB19239
    Investigational

    Tigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/​2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC.

  8. Drug

    Sabirnetug

    go.drugbank.com/drugs/DB19438
    Investigational

    Sabirnetug is under investigation in clinical trial NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)).

  9. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

  10. Drug

    Rebastinib

    go.drugbank.com/drugs/DB13005
    Investigational

    Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.